

February 24, 2022
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Notice regarding the transition to a company with
an audit and supervisory committee and nomination of directors**

Symbio Pharmaceuticals Limited (“the Company”) today announced that, pursuant to a resolution passed by the Company’s Board of Directors today, the Company will transition from a company with a board of company auditors to a company with an audit and supervisory committee. This transition aims to further strengthen corporate governance which increases the audit functionality of the Board of Directors. The transition will proceed provided that it is approved at the 17th Annual General Meeting of Shareholders scheduled for March 29, 2022.

In addition, pursuant to a resolution passed by the Company’s Board of Directors today, proposals for the election of five (5) directors (excluding directors who are Audit and Supervisory Committee members), three (3) director candidates who will be the Audit and Supervisory Committee members, and one (1) substitute member for the Audit and Supervisory Committee will be submitted to the 17th Annual General Meeting of Shareholders scheduled for March 29, 2022, as set forth below.

The partial amendment of the Articles of Incorporation in connection with this transition will be separately disclosed in the "Notice of Partial Amendment to the Articles of Incorporation" dated today.

1. Transition towards a company with an audit and supervisory committee

(1) Purpose of transition

- The Audit and Supervisory Committee members who are responsible for auditing the performance of directors. This system will further enhance corporate governance by strengthening the supervisory function of the Board of Directors and reinforcing the monitoring system.
- By allowing the Board of Directors to delegate a wide range of business decisions to directors, the Company will separate the business operation and supervision, expedite management decision-making, and enhance corporate value.

(2) Transition period

If the amended Articles of Incorporation are approved as drafted at the 17th Annual General Meeting of Shareholders scheduled for March 24, 2022, we will transition to a company with an audit and supervisory committee as of the same date.

2. Director nomination after the transition to a company with an audit and supervisory committee

(1) Nomination of candidates for the Board of Directors (excluding directors who are Audit and Supervisory Committee members)

(i) Re-nominations

Mr. Fuminori Yoshida, Representative Director, President and CEO

Mr. Shigetoshi Matsumoto, Representative Director (outside director)

Dr. Bruce David Cheson, Representative Director (outside director)

Mr. Eiji Ebinuma, Representative Director (outside director)

*Mr. Shigetoshi Matsumoto, Dr. Bruce David Cheson, Mr. Eiji Ebinuma are candidates for outside directors as defined in Article 2, Item 15 of the Companies Act.

(ii) Newly nominated

Mr. Hiroshima Ito, current Executive Vice President, Corporate Officer and COO

Profile of the candidate

April 1994	Research Scientist, Discovery Research Institute, Chugai Pharmaceutical Co., Ltd.
January 2002	Researcher, Research Center for Advanced Science and Technology, University of Tokyo
April 2005	Researcher, Forerunner Pharma Research Co., Ltd.
October 2006	Molecular Imaging Marketing Leader, GE Yokogawa Medical Systems, Inc.
March 2008	Head of Marketing Planning Department, GE Healthcare Japan Corporation
October 2012	Director of Strategic Marketing, GE Healthcare Asia Pacific
October 2014	Special Lecturer, Graduate School of Medical Engineering, Kyoto University
January 2016	Head of Headquarters Sales, GE Healthcare Japan Corporation
April 2017	Visiting Associate Professor, Graduate School of Management, GLOBIS University
October 2017	President and Representative Director, Tecan Japan Co., Ltd.
June 2018	Outside Director, Adways Inc. (current)
April 2021	Professor, Graduate School of Management, GLOBIS University (current)
February 2022	Executive Vice President, Corporate Officer and COO of the Company (current)

(2) Nomination of candidates for the Audit and Supervisory Committee

Newly nominated

Mr. Kiyoshi Watanabe, current full-time Corporate Auditor

Mr. Kesao endo, current Corporate Auditor

Mr. Yasuhiro Tamou, current Corporate Auditor

*The above candidates are candidates for outside directors as defined in Article 2, Item 15 of the

Companies Act.

(3) Nomination of Candidate as a substitute member of the Audit & Supervisory Committee

Newly nominated

Mr. Takashi Watanabe, current substitute member of the Audit & Supervisory Board (Outside)

*The above candidate is a substitute candidate for outside director as defined in Article 2, Item 15 of the Companies Act.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125